eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img


ELIQUIS (apixaban) has demonstrated superior efficacy with a comparable major bleeding rate vs. placebo in patients receiving treatment for prevention of DVT / PE recurrence1

* In patients for whom there was clinical uncertainty about the benefit of continuing treatment. Prior to the study, all patients had been treated for 6–12 months with standard anticoagulant therapy or had completed treatment with ELIQUIS or enoxaparin / warfarin as participants in the AMPLIFY trial.1


ELIQUIS dosing for your patients with DVT / PE is simple: START twice daily, STAY twice daily2

Access further resources, including treatment guidelines, patient materials and downloadable supporting materials

ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

AMPLIFY-EXT = Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy–Extended Treatment   
BD = Twice Daily   
CI = Confidence Interval   
DVT = Deep Vein Thrombosis   
LMWH = Low Molecular Weight Heparin   
N = Total number of patients in either the ELIQUIS group or the enoxaparin / warfarin group   
n = Number of patients with event   
PE = Pulmonary Embolism   
RR = Relative Risk   
SmPC = Summary of Product Characteristics   
VTE = Venous Thromboembolic Events


  1. Agnelli G et al. N Engl J Med 2013; 368: 699–708.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics.